ConductScience.org, home

Paper41805397

A two-center comparison of the efficacy of methylene blue and hydroxocobalamin for the treatment of refractory shock.

Leung NY and 4 others. Perfusion, 2026. Cited by 0 papers, by iCite.

Cite this record

ConductScience Library. A two-center comparison of the efficacy of methylene blue and hydroxocobalamin for the treatment of refractory shock. Papers, record 41805397. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41805397

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
A two-center comparison of the efficacy of methylene blue and hydroxocobalamin for the treatment of refractory shock.
PubMed
Journal
Perfusion
PubMed
Year
2026
PubMed
Publication types
Journal Article, Comparative Study, Multicenter Study, Observational Study
PubMed
Citations, by iCite
0
iCite
Revised in PubMed
2026-08-13
PubMed

Authors5

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Leung NYNatalie Yhttps://orcid.org/0009-0007-0677-0195
2Dinh CCharlene
3Nguyen LLeehttps://orcid.org/0000-0002-0254-8059
4Bakas MMirahttps://orcid.org/0009-0004-9683-9800
5Huang WTWan-Ting

Source PubMed

Download CSV of authors

Topics11

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
HydroxocobalaminMajor topic
Methylene BlueMajor topic
ShockMajor topic
Vasoconstrictor AgentsMajor topic
Humans
Female
Retrospective Studies
Male
Middle Aged
Aged
Hospital Mortality

Source PubMed

Download CSV of topics

References23

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
122911566Survival after shock requiring high-dose vasopressor therapy.Chest2013https://conductscience.org/library/papers/22911566PubMed
236505110Methylene Blue in Refractory Shock.Cureus2022https://conductscience.org/library/papers/36505110PubMed
336915146Early adjunctive methylene blue in patients with septic shock: a randomized controlled trial.Crit Care2023https://conductscience.org/library/papers/36915146PubMed
433220576Vasopressor dose equivalence: A scoping review and suggested formula.J Crit Care2021https://conductscience.org/library/papers/33220576PubMed
518768890Endogenous hydrogen sulfide regulates inflammatory response by activating the ERK pathway in polymicrobial sepsis.J Immunol2008https://conductscience.org/library/papers/18768890PubMed
619917106Association of arterial blood pressure and vasopressor load with septic shock mortality: a post hoc analysis of a multicenter trial.Crit Care2009https://conductscience.org/library/papers/19917106PubMed
737586951Hydroxocobalamin Versus Methylene Blue for the Treatment of Vasoplegic Shock Associated With Cardiopulmonary Bypass.J Cardiothorac Vasc Anesth2023https://conductscience.org/library/papers/37586951PubMed
820109575A dose-finding study of methylene blue to inhibit nitric oxide actions in the hemodynamics of human septic shock.Nitric Oxide2010https://conductscience.org/library/papers/20109575PubMed
98844239
The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine.
Intensive Care Med1996https://conductscience.org/library/papers/8844239PubMed
1028062334Intensity of Vasopressor Therapy for Septic Shock and the Risk of In-Hospital Death.J Pain Symptom Manage2017https://conductscience.org/library/papers/28062334PubMed
1137225547Hydroxocobalamin in Refractory Vasodilatory Shock: More Questions than Answers.J Cardiothorac Vasc Anesth2023https://conductscience.org/library/papers/37225547PubMed
1236174744
High-Dose IV Hydroxocobalamin (Vitamin B12) in Septic Shock: A Double-Blind, Allocation-Concealed, Placebo-Controlled Single-Center Pilot Randomized Controlled Trial (The Intravenous Hydroxocobalamin in Septic Shock Trial).
Chest2023https://conductscience.org/library/papers/36174744PubMed
1337265888Hydroxocobalamin as Rescue Therapy in a Patient With Refractory Amlodipine-Induced Vasoplegia.Cureus2023https://conductscience.org/library/papers/37265888PubMed
1412519925The pathophysiology and treatment of sepsis.N Engl J Med2003https://conductscience.org/library/papers/12519925PubMed
1530231909Refractory septic shock: our pragmatic approach.Crit Care2018https://conductscience.org/library/papers/30231909PubMed
1624151551Therapeutic strategies for high-dose vasopressor-dependent shock.Crit Care Res Pract2013https://conductscience.org/library/papers/24151551PubMed
1737147207Hydroxocobalamin for Vasodilatory Hypotension in Shock: A Systematic Review With Meta-Analysis for Comparison to Methylene Blue.J Cardiothorac Vasc Anesth2023https://conductscience.org/library/papers/37147207PubMed
1833455885Methylene Blue for Vasoplegia During Extracorporeal Membrane Oxygenation Support.J Cardiothorac Vasc Anesth2021https://conductscience.org/library/papers/33455885PubMed
1928528561Angiotensin II for the Treatment of Vasodilatory Shock.N Engl J Med2017https://conductscience.org/library/papers/28528561PubMed
2034176677Hydroxocobalamin or Methylene Blue for Vasoplegic Syndrome in Adult Cardiothoracic Surgery.J Cardiothorac Vasc Anesth2022https://conductscience.org/library/papers/34176677PubMed

See all 23 referencesDownload CSV of references

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Cited by
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/41805397

GET https://conductscience.org/api/papers/v1/41805397/references?page=2